Capital Bank & Trust’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Capital Bank & Trust’s Portfolio MRNS Stock Details MRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,030	Closed	-$8K	–	694
2020 Q1	$8K	Hold	1,030	–	–	﹤0.01%	568
2019 Q4	$9K	Hold	1,030	–	–	﹤0.01%	573
2019 Q3	$6K	Hold	1,030	–	–	﹤0.01%	596
2019 Q2	$17K	Hold	1,030	–	–	﹤0.01%	509
2019 Q1	$17K	Hold	1,030	–	–	﹤0.01%	486
2018 Q4	$12K	Hold	1,030	–	–	﹤0.01%	555
2018 Q3	$41K	Hold	1,030	–	–	﹤0.01%	482
2018 Q2	$29K	Hold	1,030	–	–	﹤0.01%	465
2018 Q1	$16K	Hold	1,030	–	–	﹤0.01%	488
2017 Q4	$34K	Hold	1,030	–	–	﹤0.01%	454
2017 Q3	$24K	Hold	1,030	–	–	﹤0.01%	432
2017 Q2	$6K	Buy	+1,030	New	+$5.57K	﹤0.01%	495

Other funds holding MRNS

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

GPCM

Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return

Capital Bank & Trust's MRNS Position: Q2 2020 in Review

Capital Bank & Trust sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q2 2020, closing a stake of 1,030 shares — an estimated $8K sold.

Capital Bank & Trust first reported a position in MRNS in Q2 2017 and held it in 12 quarters. The position peaked at $41K in Q3 2018. 94 funds tracked by Wall St. Rank hold MRNS as of Q2 2020.

Capital Bank & Trust reported no remaining Marinus Pharmaceuticals, Inc position as of Q2 2020 after selling out during the quarter.
Capital Bank & Trust sold 1,030 Marinus Pharmaceuticals, Inc shares in Q2 2020, an estimated $8K.
Capital Bank & Trust first reported a position in Marinus Pharmaceuticals, Inc in Q2 2017 and held it in 12 quarters.
Capital Bank & Trust's Marinus Pharmaceuticals, Inc position peaked at $41K in Q3 2018.
94 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q2 2020.

Based on Capital Bank & Trust's 13F filing for Q2 2020, filed 14 Aug 2020.